# KM08 Preference Label 1 - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_247_Merrow - Task 1l71a77d, batch 20260612_082331).
Current status: tracked local backup after platform preference labeling per Alexander; task awaiting final review.

Studio-selected pair:
- Transcript A = 0.150, 55 steps, 19m 54s.
- Transcript B = 0.200, 37 steps, 14m 23s.
- Bundle IDs not shown in the pasted transcript; record from the download icons on submit.

Evidence read: the pasted PL transcript, including both final output summaries. This is the all-floor task (KM08 v7, job 062652b2, ten runs in the 0.15 to 0.30 band, no live catcher). The bedside-photo miss is the designed legitimate failure, so this pair is a both-floor severity comparison, not a pass-versus-fail contrast. A = 0.15 and B = 0.20 are both floors in the banked vector.

KEY FINDING: B is better, slightly. Both trajectories make the correct gabapentin call (decline the 300 mg TID escalation, hold at 300 mg nightly) and both commit the central designed failure: the bedside photo shows a plantar diabetic foot lesion (a callus with a central open area), and both write false reassurance that there is no ulceration or open wound, then finalize the note for discharge with no bedside wound examination, infection or depth or drainage assessment, offloading, wound care, or podiatry or wound follow-up. Neither output is safe. B edges A on two points. A offers to escalate gabapentin to a BID step if the user prefers, which reopens the renally cleared sedating drug it just correctly held, and A gives confident enumerated "no acute skin findings" reassurance. B is more careful about the photo (flags that the read is limited at photo resolution and defers to the bedside exam as the reliable source) and firmly closes the dose with explicit patient and family teaching. A's one merit, adding daily foot checks and a discharge skin inspection, is real but still does not act on the lesion and does not offset. The difference is degree, not a materially safer deliverable, so tier 1.

VERDICT: B1 (B better, slightly). Button = plain B (no plus sign).

## Justification

Preferred output: B

On a task where neither output is safe, B produces the marginally less harmful discharge note. Both correctly decline the gabapentin 300 mg TID escalation and hold at 300 mg nightly, and both miss the central finding: the bedside photo shows a plantar diabetic foot lesion, and both state there is no ulceration or open wound and then finalize the addendum for same-day discharge with no wound workup. B is preferred only because A adds two avoidable harms that B does not. A offers to escalate gabapentin to a BID step if the user prefers, which puts the renally cleared sedating drug it just held back on the table in a patient with CKD stage 3 and AKI resolved only the prior day, nephrology's renal-dose-review directive, OSA with variable CPAP adherence, and Morse 65 fall risk. And A gives more confident false reassurance, enumerating "no open wound, ulceration, focal erythema, dressing, or asymmetric swelling" and concluding "no acute skin findings." B keeps the dose firmly closed and is more guarded about what the photo can exclude.

Justification: The golden and grader reward acting on the visible foot lesion before discharge, with a bedside foot exam, infection and depth and drainage assessment, offloading, wound care, and podiatry or wound follow-up, even when gabapentin is safely held. Neither A nor B does this; both convert a discharge-day foot lesion into chronic neuropathic pain and poor sleep and sign the note off. Because both commit the central failure, this is a severity comparison rather than a pass versus fail, and B leads by a narrow margin, so the rating is plain B rather than B+.

Prompt adherence: Both complete the open overnight comfort and sleep item, finalize the SOAP addendum, preserve the note format and header, remove draft status language, and save a sign-ready DOCX. Both answer the requested workflow. Tie.

Correctness: Both make the correct gabapentin decision and both make the decisive clinical error of false reassurance that the photo shows no wound. A is worse on correctness. It offers to escalate gabapentin to BID on request, which is unsafe to put on the table given the renal, OSA, and fall-risk picture, and its enumerated "no acute skin findings" is more confident false reassurance than B's hedged "no identifiable ulcer or wound at photo resolution." B is wrong on the photo too, but is more guarded and does not reopen the dose.

Completeness: A adds daily foot checks and a bedside skin inspection at discharge teaching, which B does not, so A gestures slightly further toward the foot. But neither arranges what the lesion requires (depth, drainage, and infection assessment, offloading, wound care, and podiatry or wound follow-up), so both are incomplete on the central item. A's added surveillance does not reach that bar and does not offset its escalation offer. This is the one dimension with a slight edge to A.

Methodology: Both read the chart broadly and both verify the home gabapentin dose against the MAR, the pharmacy fill history, and the medication reconciliation. Both analyze the photo with pixel and OCR methods and conclude no wound rather than reading it as a clinical image of a plantar lesion, which is the shared methodological miss. A then weakens its own conclusion by offering to revise toward escalation, while B holds a single committed disposition.

Quality and clarity: Both are organized and sign-ready. B reads as the cleaner final document because it closes the dose question with explicit patient and family teaching and a resolved handoff line. A's closing offer to escalate if asked leaves the central medication decision visibly open in a note that is meant to be ready to sign, which is both a safety and a finalization weakness.

Summary: B is preferred at plain B because, on an all-floor task where both outputs miss the discharge-day foot lesion, B is the marginally safer note: it holds gabapentin firmly and is more careful about the photo's limits, while A offers an unsafe BID escalation and gives more confident false reassurance. The margin is plain B rather than B+ because both commit the same central failure and the difference is degree, not a materially safer deliverable.

## Guardrails (must survive any edit)
1. Preferred output is B.
2. Use plain B (no plus). Both outputs floor on the same central photo-miss; the gap is severity, not pass versus fail, so do not escalate to B+ unless the downloaded final A note actually writes a gabapentin escalation into the orders rather than only offering one.
3. The decider is A's BID-escalation offer plus its more confident "no acute skin findings" reassurance, set against B's firmer dose closure and photo-resolution caution. It is not prose polish or step count.
4. Do not credit either output for safety on the foot lesion; neither examines, offloads, or refers it. A's daily foot checks are a minor completeness point only.
5. KM08 is an all-floor task with no live catcher; this is a both-floor severity pair by design. This is PL 1 of 3 for KM08, now tracked as a submitted-stage local backup per Alexander.

## Submit Mechanics
Select plain B (no plus sign), paste the justification from "Preferred output: B" through "Summary" into Comments, submit the preference, confirm it appears in submission history, then run Preference Labels AutoQC. Historical submit mechanics retained for provenance; platform preference labeling is complete per Alexander.
